Neuroprotection for ischaemic stroke: An unattainable goal?

CNS Drugs

Volumn 15, Issue 3, 2001, Pages 165-174

  Liebeskind, D S ^a   Kasner, S E ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (5 CHLORO 2 METHOXYPHENYL) 3 FLUORO 2,3 DIHYDRO 6 TRIFLUOROMETHYL 1H INDOL 2 ONE; ARUNDIC ACID; CLOMETHIAZOLE; DISUFENTON SODIUM; FLUOROCARBON; GLYCERYL TRINITRATE; LDP 01; MAGNESIUM; NEUROPROTECTIVE AGENT; REPINOTAN; UNCLASSIFIED DRUG; [1,2,3,4 TETRAHYDRO 7 (1H IMIDAZOL 1 YL) 6 NITRO 2,3 DIOXO 1 QUINOXALINYL]ACETIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; CEREBROVASCULAR ACCIDENT; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG DESIGN; DRUG MECHANISM; DRUG RESEARCH; HUMAN; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0035073912     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200115030-00001     Document Type: Review

References (66)

1. Tissue plasminogen activator for acute ischemic stroke
2. A systems approach to immediate evaluation and management of hyperacute stroke: Experience at eight centers and implications for community practice and patient care
3. Thrombolytic therapy for acute ischemic stroke: Why the majority of patients remain ineligible for treatment
4. Thrombolysis in acute ischemic stroke: Controlled trials and clinical experience
5. Why do neuroprotective drugs work in animals but not humans?
6. Neuroprotection for acute stroke: Making clinical trials work
7. Animal models of stroke
8. Neuroprotective therapy
9. Neuroprotection disappointment yet aGAIN
10. Clinical trials with neuroprotective drugs in acute ischaemic stroke: Are we doing the right thing?
11. Clinical trials with neuroprotective drugs in acute ischaemic stroke: Are we doing the right thing?
12. Neuroprotection in acute ischaemic stroke: A tale of for whom the bell tolls?
13. Neuroprotection in acute ischaemic stroke: Current status and future potential
14. Neuroprotective strategies in nature: Novel clues for the treatment of stroke and trauma
15. Which targets are relevant for therapy of acute ischemic stroke?
16. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: A randomised controlled trial
17. Phase II studies of the glycine antagonist GV150526 in acute stroke: The North American experience
18. Identification and pharmacological characterisation of GV150526, a novel glycine antagonist as a potent neuroprotective agent
19. Biology of ischemic cerebral cell death
20. Neuroprotection in acute ischaemic stroke II: Clinical potential
21. Brain protection: Human data and potential new therapies
22. Recently developed neuroprotective therapies for acute stroke: A qualitative systematic review of clinical trials
23. The ischemic penumbra
24. Viability thresholds and the penumbra of focal ischemia
25. Clinical experience with excitatory amino acid antagonist drugs
26. Neuroprotective properties of calciumchannel blockers
27. Ischemic stroke: Today and tomorrow
28. Cytoprotective therapies in stroke
29. Oxidative stress in the context of acute cerebrovascular stroke
30. Inflammatory mediators and stroke: New opportunities for novel therapeutics
31. The role of inflammation after acute stroke: Utility of pursuing anti-adhesion molecule therapy
32. Cytokines and adhesion molecules in stroke and related diseases
33. The changing landscape of ischaemic brain injury mechanisms
34. Neuroprotection by the inhibition of apoptosis
35. Meta-analysis of acute stroke trials employing neuroprotective agents
36. Safety and tolerability of 619C89 after acute stroke
37. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke
38. Selfotel in acute ischemic stroke: Possible neurotoxic effects of an NMDA antagonist
39. Safety and tolerability study of aptiganel hydrochloride in patients with an acute ischemic stroke
40. Remacemide hydrochloride: A doubleblind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke
41. Clinical trial of nimodipine in acute ischemic stroke
42. A randomized efficacy trial of citicoline in patients with acute ischemic stroke
43. Lubeluzole in acute ischemic stroke: A double-blind, placebo-controlled phase II trial
44. Lubeluzole treatment of acute ischemic stroke
45. Multinational randomised controlled trial of lubeluzole in acute ischaemic stroke
46. Prophylactic pharmacologic neuroprotection against focal cerebral ischemia
47. Neuroprotection as initial therapy in acute stroke
48. Duration of neuroprotective treatment for ischemic stroke
49. Prophylactic neuroprotection for cerebral ischemia
50. Combination drug therapy and mild hypothermia: A promising treatment strategy for reversible, focal cerebral ischemia
51. The future of stroke treatment
52. Recommendations for standards regarding preclinical neuroprotective and restorative drug development
53. Improving the quality of reporting of randomized controlled trials. The CONSORT statement
54. Stroke therapy in traditional Chinese medicine (TCM): Prospects for drug discovery and development
55. Neuroprotective effects of estrogens: Potential mechanisms of action
56. Estrogen as a neuroprotectant in stroke
57. Considerations in the design of clinical trials of neuroprotective therapy in acute stroke
58. Animal models of acute ischaemic stroke: Can they predict clinically successful neuroprotective drugs?
59. The RANTTAS Investigators: Infarct volume as a surrogate or auxiliary outcome measure in ischemic stroke clinical trials
60. S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke
61. Using pathophysiology in acute stroke trials
62. The effect of citicoline on lesion volume in acute stroke: A multicenter, double-blind placebo-controlled trial
63. Quality of acute ischemic stroke trials: Time trends and effect of funding source
64. Empiric evidence of publication bias affecting acute stroke clinical trials
65. What questions can large, simple trials answer?
66. Families of trials: The answers to all our questions?